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for moxifloxacin on day 1 and day 24. In treatment group B, placebo 
for ponesimod was administered once daily for 22 days (days 2–23). 
In addition, subjects received a single oral dose of moxifloxacin 400 
mg either on day 1 or day 24. Replicate ECGs were to be extracted 
from the continuous digital 12-lead ECG recording over 12 hours. 
Primary end point was the baseline-adjusted, placebo-corrected 
effect of individual nonlinear corrected QT intervals (Δ Δ QTcI) on 
day 12 (40 mg) and on day 23 (100 mg). The relationship between 
plasma concentrations of ponesimod and metabolites and Δ Δ QTcI 
was assessed by applying a linear mixed effects modeling approach.
Results: Ponesimod caused a small QTc prolongation, with a mean 
peak effect on Δ Δ QTcI of 6.9 ms (upper bound of the 2-sided 90% 
CI, 11.3 ms) on 40 mg and 9.1 ms (upper bound of the 2-sided 90% 
CI, 14.0 ms) on 100 mg. However, upon extrapolation to steady-state 
concentrations reached with 20-mg ponesimod, the upper bound of 
the 2-sided 90% CI would be below 10 ms, and should result in a 
negative study for doses of 20-mg ponesimod or lower. There was no 
relevant increased incidence of QTcI outliers, either as absolute or 
change from baseline, and QTcI > 480 ms or QTcI increase > 60 ms 
from baseline was not observed with ponesimod. Ponesimod did not 
affect the PR or QRS intervals. Assay sensitivity was demonstrated by 
moxifloxacin QTcI response with a mean peak effect on Δ Δ QTcI of 
11.8 ms (lower bound of the 2-sided 90% CI, 9.0 ms).
Conclusion: Ponesimod at doses of 40 mg and 100 mg causes a 
small QTc prolongation. However, based on the concentration-effect 
relationship no clinically relevant effect on QTc interval is expected 
for a dose of 20 mg, the highest selected dose for Phase 3.
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Actelion Pharmaceuticals Ltd, employee of Actelion Pharmaceuticals 
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Introduction: Hypoxia is associated with pro-inflammatory condi-
tions and increased risk of cardiovascular diseases. The transcription 
factors hypoxia-inducible factor (HIF)-1 and HIF-2 are known to 
have central roles in oxygen and energy homeostasis. Recent studies 
have shown that HIF-2α is deacetylated and activated by Sirtuin 
(Sirt)1, a nicotinamide adenine dinucleotide (NAD)-dependent 
deacetylase, suggesting that Sirt1 may be involved in resistance to 
hypoxic stress. The aim of our pilot study is to investigate the acute 
role of Sirt in adaptation to hypoxic conditions.
Patients (or Materials) and Methods: Five healthy volunteers inhaled 
a gas mixture of 10% oxygen in nitrogen for 4 to 6 hours. Blood 
samples were taken 2, 4, 6 to 8, and 24 hours after start of inhalation. 
Erythropoietin levels were measured in plasma, and hemoxygenase 1 
(HO-1), nicotinamide phosphoribosyltransferase (Nampt) and Sirt 
levels in peripheral blood mononuclear cells (PBMCs) by Western 
blot and qPCR.
Results: During inhalation of the 10% oxygen gas mixture, paO2 
levels decreased from a mean of 90 mm Hg to 50 mm Hg. Mean 
erythropoietin levels increased from 6.6 to 11.7 mU/mL 6 to 8 hours 
after the start of inhalation. Western blot analysis showed increased 
expressions of HO-1 and Sirt3 after 6 hours. The expression of the 
Sirt substrate Nampt was also increased after 6 and 24 hours. In 
contrast, only a small increase in Sirt1 and Sirt3 mRNA was detected. 
Sirt2 mRNA or protein expression was not altered following hypoxia.
Conclusion: Systemic hypoxia increases Sirt3 protein expression in 
PBMC. This suggests that histone deacetylation of hypoxia-inducible 
factors are affected by changes in Sirt expression in diseases with 
intermittent hypoxia. Drugs targeting Sirt may thus influence adap-
tation to acute hypoxic episodes such as sleep apnea syndrome or 
chronic hypoxic conditions.
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Introduction: In patients undergoing coronary artery bypass graft-
ing (CABG), ischemia-reperfusion (IR) damages myocardial tissue. 
Postoperative plasma troponin is a biomarker of myocardial injury 
and is associated with an adverse outcome. In animals, dipyrida-
mole reduces reperfusion injury by inhibition of the equilibrative 
nucleoside transporter (ENT) and subsequent increase in extracel-
lular adenosine (an activator of intracellular prosurvival pathways). 
In humans, oral dipyridamole significantly inhibits ENT. Cellular 
uptake of adenosine is reduced in subjects with reduced adenosine 
monophosphate deaminase 1 (AMPD1) activity. We hypothesized 
that oral dipyridamole limits myocardial IR-injury in patients under-
going CABG surgery and that this protection is limited to those with 
normal AMPD1 activity.
Patients (or Materials) and Methods: In a double-blind trial, 94 
patients undergoing elective CABG were randomized to pretreat-
ment with either dipyridamole retard (200 mg BID for 3 days) or 
placebo. Patients abstained from caffeine for at least 24 hours. The 
primary end point: plasma troponin-I at 6, 12, and 24 hours after 
CABG (high sensitivity assay, Siemens). Secondary end points bleed-
ing, arrhythmias 24 hours’ postoperatively, the need for prolonged 
inotropic support, and prolonged ICU stay. In all patients, AMPD1 
34C> T variants (CC: normal activity; CT and TT: reduced activity) 
was determined.
Results: Seventy-nine patients were included in the per-protocol 
analysis (46 placebo). Treatment arms did not differ with respect to 
age, gender, cardiovascular medication, cardiovascular risk factors, 
or aortic clamping time. Troponin concentrations increased from 0 
(0–0) to maximally 3.4 (2.4–5.5) in placebo and 3.7 (2.7–6.1) μ g/L 
at 6 hours after reperfusion (median with interquartile range; P > 
0.5 for comparison between treatment arms, mixed model analysis 
after log transformation).This increase in troponin was correlated 
with aortic clamping time (r = 0.3, P < 0.01, Spearman). As for the 
primary end point, secondary end points did not significantly differ 
between the 2 study arms. Analysis restricted to the AMD1 CC vari-
ant provided similar results.
Conclusion: Dipyridamole before CABG does not prevent the rise 
in troponin, regardless of AMPD1 genotype. We confirmed a role 
for IR in this measure of cardiac injury. Therefore, dipyridamole 
does not seem an effective therapy to prevent ischemia-reperfusion 
injury in humans.
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Introduction: JNJ-26489112 appeared in animal models as a cen-
trally active, broad spectrum anticonvulsant. A Phase-IIa placebo-
controlled, single-blind Proof of Concept study was performed to 
explore dose-related anticonvulsant effects in epilepsy patients.
Patients (or Materials) and Methods: Twelve adult Caucasian 
patients (3 men, 9 women; age, 18–40) with idiopathic photosensi-
tive epilepsy underwent standardized photic stimulation during scalp 
EEG recording. Photosensitivity ranges (SPR) were determined before 
and at hourly intervals for up to 8 hours and at 12 hours after receiv-
ing a single oral dose of placebo on day 1, JNJ-26489112 on day 
2, and a second dose of placebo on day 3. One patient withdrew 
after day 1. A positive response was defined as abolishment of the 
epileptogenic response or reduction in at least 3 out of 4 consecu-
tive time points on either day 2 or day 3 compared with baseline 
day 1. The difference in SPR at each time point on day 2 and day 3 
were calculated relative to matched time points on day 1 and plot-
ted versus time for each patient. The type of response (ie, positive 
response or complete suppression) and number of responders were 
summarized by dose level. Cohorts of 4 patients were dosed 1000, 
2000, or 3000 mg, respectively, and blood samples taken after each 
EEG photosensitivity measure. Safety was assessed by the reporting 
of adverse events, vital signs, 12-lead ECG, physical and neurological 
examinations, and laboratory assessments.
Results: Ten of 11 patients (91%) showed a clear pharmacodynamic 
effect starting on dosing day 2, with a dose-dependency for complete 
suppression.The median Tmax of JNJ-26489112 (range, 3.73–5.04 
hours) in plasma was similar across all 3 dose groups and plasma 
exposure increased proportionally with dose; concentrations of 
other AEDs did not appear to be effected by coadministration of 
JNJ-26489112. Most frequent adverse events reported being mild 
headache, dizziness, and nausea.
Conclusion: Single oral doses of JNJ-26489112 were well tolerated 
and exhibited dose-related antiepileptic effects in patients with idi-
opathic, photosensitive epilepsy.
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Introduction: Increased heart rate is a significant predictor of death 
and hospitalization in heart failure patients. Risk increases directly 
with increasing heart rate above 60 beats/min. These lead to the 
hypothesis that lowering heart rate with the If inhibitor, ivabradine, 
could be beneficial for cardiac function and clinical outcomes in heart 
failure patients.
Patients (or Materials) and Methods: A total of 309 stable IHF 
patients attending Sultan Qaboos University Hospital, Cardiology 
Clinic, were screened. Qualified patients were enrolled in the study 
and were randomly allocated to 2 groups: carvedilol up to 25 mg BID 
(group I) and carvedilol/ivabradine up to 25/7.5 mg BID (group II). 
The duration of follow-up was 6 months. The average daily dose of 
ivabradine was 5.8 mg. The average daily dose of carvedilol was 16.2 
mg and 11.4 mg in group I and in group II respectively.
Results: Resting HR decreased in both groups from 82.6 (12) to 
72.9 (12.7) beats/min in group 1 (P = 0.05); and from 85.3 (9.7) to 
68.5 (9.4) beats/min in group II (P = 0.05). The reduction in HR was 
significantly higher in the combination group [(diff = 7.3 beats/min, P 
= 0.03)]. There was a significant increment in left ventricular ejection 
fraction (LVEF) in group II by 4.6 (5.9)% (P = 0.01), whereas no 
significant change was observed in group I. The reduction in HR due 
to ivabradine was associated with pronounced increment in health-
related quality of life and reduction of incidence of admission events 
to hospital with worsening heart failure. Ivabradine in combination 
with carvedilol was associated with nonsignificant asymptomatic 
bradycardia (P = 0.08).
Conclusion: Combining ivabradine to carvedilol in stable ischemic 
heart failure patients with heart rate faster than 70 beats/min was 
associated with better heart rate reduction, improvement of quality 
of life, and reduced rehospitalization. Risk of bradycardia should 
be taken in consideration when ivabradine is used with carvedilol
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Introduction: Combining the regulatory requirement to obtain 
human mass balance and metabolism data along with determin-
ing absolute oral bioavailability and clearance data for new drugs 
requires an ability to formulate and manufacture both intravenous 
and oral drug products at microtracer and therapeutic doses, respec-
tively, along with the ability to correctly implement accelerator mass 
spectrometry (AMS) to provide the differential analysis required for 
14C intravenous drug product.
Patients (or Materials) and Methods: We will describe variations of 
integrated study design, combining intravenous microtracer doses 
with the conventional human mass balance study either as a crossover 
study in the same subjects or as a parallel group study in separate 
cohorts of subjects to deliver a material, time and cost efficient study 
that is rich in PK and metabolism data to support regulatory sub-
mission. In the microtracer part of the study, intravenous levels of 
14C parent drug are generated by AMS analysis and absolute bio-
availability data is generated by comparison against conventional 
liquid chromatography-mass spectrometry (LC-MS/MS) analysis of 
unlabeled orally administered drug. Mass balance data are generated 
after administration of a 14C labeled oral dose in a second period 
of the study utilizing liquid scintillation counting to determine 14C 
recovery from excreta. Metabolite profiling and identification is also 
performed from the samples collected at this part of the study.
Results: A variety of study designs and summary data from com-
pleted studies will be reviewed, and the benefits and merits of the 
design over conventional approaches to generate such data will be 
discussed. This will include evaluation of time and dose-dependent 
